Showing 4051-4060 of 9737 results for "".
- Derm-Biome Pharmaceuticals, Massachusetts General Hospital Partner for Skin Cancer Study of New Topical Rxhttps://practicaldermatology.com/news/derm-biome-pharmaceuticals-massachusetts-general-hospital-partner-for-skin-cancer-study-of-new-topical-rx/2462157/Derm-Biome Pharmaceuticals Inc. is collaborating with Massachusetts General Hospital for a study looking at Derm-Biome’s second-generation topical treatment for precancerous skin conditions and non-melanoma skin cancers. The topical is highly sel
- Take That, Melanoma! ATM Kinase Inhibitors May Stop Metastasishttps://practicaldermatology.com/news/take-that-melanona-atm-kinase-inhibitors-may-stop-metastasis/2462146/Ataxia telangiectasia mutated (ATM) kinase inhibition may target the metastatic capacity of melanoma cells, according to a research team led by Wolfgang Weninger and Shweta Tikoo from MedUni Vienna's Department of Dermatology. The results of the study, which appe
- AI In Action: Almirall, Absci AI Drug Discovery Partner to Rapidly Develop New treatments for Skin Diseaseshttps://practicaldermatology.com/news/ai-in-action-almirall-absci-ai-drug-discovery-partner-to-rapidly-develop-new-treatments-for-skin-diseases/2462135/Almirall S.A. and Absci Corporation, a generative artificial intelligence (AI) drug creation company, are teaming up to develop and commercialize AI-designed therapeutics to treat dermatological diseases. The partnership combines Absci’s Integrated Drug C
- Study: Bakuchiol-containing Skin Care Regimen Improves Skin Barrier Function Without Disrupting the Microbiomehttps://practicaldermatology.com/news/study-bakuchiol-containing-skin-care-regimen-promotes-microbiome-health-in-sensitive-skin/2462104/A Burt’s Bees bakuchiol-containing skin care regimen can help maintain a balanced skin barrier and microbiome in people with sensitive skin, according to research presented at the 2023 Integrative Dermatology Symposium (IDS). For the study, 45 women aged 35 to 70 years with sensit
- Biosimilar News: YUFLYMA Added to CarePartners Specialty Pharmacy Cost Savings Programshttps://practicaldermatology.com/news/biosimilar-news-yuflyma-added-to-carepartners-specialty-pharmacy-cost-savings-programs/2462100/Celltrion USA, Inc.’s US Food and Drug Administration-approved biosimilar, YUFLYMA (adalimumab-aaty) has been added to CarePartners Specialty Pharmacy Cost Savings Programs. YUFLYMA is a high-concentration (100mg/mL) and citrate-free formulation of the Humira (adal
- Almirall Seeks Proposals to Better Understand Key Pathological Mechanisms of Skin Diseaseshttps://practicaldermatology.com/news/almirall-seeks-proposals-to-better-understand-key-pathological-mechanisms-of-skin-diseases/2462090/Almirall S.A. is calling for proposals to better understand key pathological mechanisms of several skin diseases through AlmirallShare, its open innovation platform. Almirall’s objective through this call is to identify and explore, through collaboration w
- InMode: Employees in Isreal Are Safehttps://practicaldermatology.com/news/inmode-employees-in-isreal-are-safe/2462053/InMode Ltd. has affirmed the safety of the employees at the Company's Yokneam, Israel headquarters and does not anticipate any interruption in productionas a result of the Israel-Hamas War, "InMode is committed to supporting all customers, distributors, employees, and
- DecisionDx-Melanoma Outperforms MSKCC Nomogram in Predicting Sentinel Lymph Node Positivity in Melanomahttps://practicaldermatology.com/news/decisiondx-melanoma-outperforms-mskcc-nomogram-in-predicting-sentinel-lymph-node-positivity-in-melanoma/2462044/Castle Biosciences, Inc.’s DecisionDx-Melanoma outperformed a nomogram developed at the Memorial Sloan Kettering Cancer Center (MSKCC) in predicting the risk of sentinel lymph node (SLN) positivity in patients with cutaneous melanoma (CM), according to a new study in
- Cabaletta Bio Receives FDA Clearance of IND Application for Treatment of Systemic Sclerosis with CABA-201https://practicaldermatology.com/news/cabaletta-bio-receives-fda-clearance-of-ind-application-for-treatment-of-systemic-sclerosis-with-caba-201/2462036/The U.S. Food and Drug Administration (FDA) is allowing Cabaletta Bio, Inc.’s third Investigational New Drug (IND) application for CABA-201 to proceed. for a Phase 1/2 study in patients with systemic sclerosis (SSc). CABA-201 is a 4-1BB-containing fully human CD19-CAR T cell
- Positive Topline Results Seen for Roflumilast Cream 0.05% in Young Kidshttps://practicaldermatology.com/news/positive-topline-results-seen-for-roflumilast-cream-005-in-young-kids/2462010/Arcutis Biotherapeutics, Inc.’s roflumilast cream 0.05% met all primary endpoint and all secondary endpoints in children aged 2 to 5 years with mild to moderate atopic dermatitis (AD), according to results from the INTEGUMENT-PED pivotal Phase 3 trial. In